Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.

MLA

Laloi, Louise, et al. “Retrospective, Real‐life Study of Venetoclax plus Azacitidine or Low‐dose Cytarabine in French Patients with Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy.” Cancer Medicine, vol. 12, no. 6, Mar. 2023, pp. 7175–81. EBSCOhost, https://doi.org/10.1002/cam4.5459.

APA

Laloi, L., Billotey, N. C., Dumas, P., Paul, F., Villate, A., Simand, C., Fornecker, L., Puisset, F., Bertoli, S., Simonet, M. B., Laribi, K., Houyou, D., Santagostino, A., Michel, C., Guepin, G. R., Guerineau, E., Tabrizi, R., Hunault, M., Giltat, A., & Kaphan, E. (2023). Retrospective, real‐life study of venetoclax plus azacitidine or low‐dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy. Cancer Medicine, 12(6), 7175–7181. https://doi.org/10.1002/cam4.5459

Chicago

Laloi, Louise, Natacha Chaumard Billotey, Pierre‐Yves Dumas, Franciane Paul, Alban Villate, Célestine Simand, Luc Fornecker, et al. 2023. “Retrospective, Real‐life Study of Venetoclax plus Azacitidine or Low‐dose Cytarabine in French Patients with Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy.” Cancer Medicine 12 (6): 7175–81. doi:10.1002/cam4.5459.